Extrapulmonary Effects of Chronic Obstructive Pulmonary Disease on Physical Activity

Watz, Henrik; Waschki, Benjamin; Boehme, Corinna; Claussen, Martin; Meyer, Thorsten; Magnussen, H

doi:10.1164/rccm.200707-1011oc

Cited by 351 publications

(339 citation statements)

References 48 publications

Supporting

Mentioning

284

Contrasting

Unclassified

Order By: Relevance

“…Details of the COPD population at the institute have been published previously [13]. Patients with COPD had to be free of an exacerbation for at least 2 months.…”

Section: Study Populationmentioning

confidence: 99%

“…It incorporates a biaxial accelerometer that records steps per day, and physiological indicators of energy expenditure. In patients with COPD, the SenseWear Pro armband provides a valid and reproducible estimate of energy expenditure during walking at a slow to moderate pace in a laboratory setting [12], and a high correlation between steps per day and movement counts as measured by a different accelerometer [13].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Physical activity in patients with COPD

Watz¹,

Waschki²,

Meyer³

et al. 2008

European Respiratory Journal

580

525

View full text Add to dashboard Cite

“…Details of the COPD population at the institute have been published previously [13]. Patients with COPD had to be free of an exacerbation for at least 2 months.…”

Section: Study Populationmentioning

confidence: 99%

mentioning

confidence: 99%

Physical activity in patients with COPD

Watz¹,

Waschki²,

Meyer³

et al. 2008

European Respiratory Journal

580

525

View full text Add to dashboard Cite

“…Measurement of B-type natriuretic peptide or N-terminal prohormone brain natriuretic peptide (NT-proBNP) is a good way to discriminate heart failure in COPD patients [98] and may be useful to distinguish acute COPD exacerbations from decompensated heart failure [99]. An elevated plasma NTproBNP is correlated with poor physical activity in COPD patients, suggesting that left defective left ventricular function may contribute to reduced performance [100]. There is some evidence that, if anything, the cardiac size is decreased at least in patients with emphysema and that the actual volume of intra-thoracic blood is also decreased in patients with hyperinflation.…”

Section: Cardiovascular Diseasementioning

confidence: 99%

Systemic manifestations and comorbidities of COPD

Barnes¹,

Celli²

2009

European Respiratory Journal

1,465

1,113

View full text Add to dashboard Cite

Increasing evidence indicates that chronic obstructive pulmonary disease (COPD) is a complex disease involving more than airflow obstruction. Airflow obstruction has profound effects on cardiac function and gas exchange with systemic consequences. In addition, as COPD results from inflammation and/or alterations in repair mechanisms, the ''spill-over'' of inflammatory mediators into the circulation may result in important systemic manifestations of the disease, such as skeletal muscle wasting and cachexia. Systemic inflammation may also initiate or worsen comorbid diseases, such as ischaemic heart disease, heart failure, osteoporosis, normocytic anaemia, lung cancer, depression and diabetes. Comorbid diseases potentiate the morbidity of COPD, leading to increased hospitalisations, mortality and healthcare costs. Comorbidities complicate the management of COPD and need to be evaluated carefully. Current therapies for comorbid diseases, such as statins and peroxisome proliferator-activated receptor-agonists, may provide unexpected benefits for COPD patients. Treatment of COPD inflammation may concomitantly treat systemic inflammation and associated comorbidities. However, new broad-spectrum anti-inflammatory treatments, such as phosphodiesterase 4 inhibitors, have significant side-effects so it may be necessary to develop inhaled drugs in the future. Another approach is the reversal of corticosteroid resistance, for example with effective antioxidants. More research is needed on COPD comorbidities and their treatment.

show abstract

“…It was also found to be significantly increased in patients presenting with acute exacerbation of COPD. de Torres and co workers [29] indicated that serum CRP level significantly increased with the aggravation of disease and correlation was found with BODE index(r=0.17, p=0.050).A cross-sectional study performed by Henrik Watz et al [30] states that higher values of CRP are associated with reduced physical activity in patients with COPD. Sarioglu et al [31] investigated the relationship between the BODE index and disease duration, annual exacerbation and hospitalization rates, health related quality of life and systemic inflammatory markers like C-reactive protein and concluded that BODE index is a comprehensive, feasible and simple clinical scoring system in the evaluation of COPD.…”

Section: Discussionmentioning

confidence: 95%

Study of Prognostic Association of C-Reactive Protein (A Biomarker) with Clinically Important Predictors of Outcome in Stable and Unstable COPD Patients

2016

AIMDR

View full text Add to dashboard Cite

Background: COPD is characterized by persistent airflow limitation that is progressive and is associated with enhanced chronic inflammatory response in the airways to noxious particles or gases. It has both systemic and pulmonary effects. Since COPD deaths estimated to increase by 30% in next 10 years, cost of treatment will be a heavy burden on global economy. The costs are proportional to pulmonary and extra pulmonary components of the disease. Methods: In this study, we examined 100 patients of COPD, out of which 80 were stable and 20 were unstable. Results: CRP levels were found to be increased in cases more than in controls (13.55+10.83 vs. 2.07+0.82 mg/lit, p<0.001), the levels being higher in unstable patients than in stable patients (33.78+7.74 vs. 8.50+1.81 mg/lit, p<0.001). We also submitted the patients to MMRC dyspnoea scale and found that CRP is positively correlated with MMRC dyspnoea scale (r=0.638, p<0.001) and was inversely correlated with 6-minute walk distance (r= -0.364, p<0.001). There was a significant positive correlation of CRP with BODE index (r=0.780, p<0.001). Conclusion: The study is valuable in detecting the severity of COPD cases both in stable and unstable conditions and to forecast the future morbidity and mortality outcome of such cases.

show abstract

Extrapulmonary Effects of Chronic Obstructive Pulmonary Disease on Physical Activity

Abstract: Higher values of systemic inflammation and left cardiac dysfunction are associated with reduced physical activity in patients with COPD.

Cited by 351 publications

References 48 publications

Physical activity in patients with COPD

Physical activity in patients with COPD

Systemic manifestations and comorbidities of COPD

Study of Prognostic Association of C-Reactive Protein (A Biomarker) with Clinically Important Predictors of Outcome in Stable and Unstable COPD Patients

Contact Info

Product

Resources

About